Selected article for: "activity broad spectrum and adenosine analog"
Author: Taha, Huda R.; Keewan, Nour; Slati, Farah; Al-Sawalha, Nour A.
Title: Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic
  • Cord-id: 3l31aj19
  • Document date: 2021_8_10
    • ID: 3l31aj19
    Snippet: BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiology of COVID-19 pandemic, resulted in significant harm to the affected countries in every aspect of life. The virus infected over 139 million patients and resulted in over 2.9 million deaths until April 16, 2021. New variants of this virus were identified that spread rapidly worldwide. SUMMARY: Remdesivir, a prodrug of adenosine nucleotide analog, is an antiviral with a broad spectrum of activity that was test
    Document: BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiology of COVID-19 pandemic, resulted in significant harm to the affected countries in every aspect of life. The virus infected over 139 million patients and resulted in over 2.9 million deaths until April 16, 2021. New variants of this virus were identified that spread rapidly worldwide. SUMMARY: Remdesivir, a prodrug of adenosine nucleotide analog, is an antiviral with a broad spectrum of activity that was tested on SARS and Middle East respiratory syndrome infections. In vitro studies conducted on SARS-CoV-2 revealed that remdesivir inhibited viral replication with high selectivity index in cell cultures. In vivo studies showed that remdesivir reduced viral load in bronchoalveolar lavage fluid and attenuated pulmonary infiltrates in infected animals. Further, remdesivir showed promising results in terms of clinical improvement, shortening the recovery time, mortality rate, and the duration of oxygen need, despite that some clinical trials did not reveal significant effect on remdesivir use. Several studies showed positive results of remdesivir against the new variants. KEY MESSAGES: Remdesivir showed a promising beneficial effect against new variants of SARS-CoV-2, but more clinical evidence is needed to confirm this effect.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and liver tissue biopsy: 1
    • acute ards respiratory distress syndrome and loading dose: 1
    • acute ards respiratory distress syndrome and local inflammatory response: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and low capacity: 1
    • acute ards respiratory distress syndrome and low concentration: 1
    • acute ards respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute ards respiratory distress syndrome and low mortality rate: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and low normal: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and low variation: 1
    • acute ards respiratory distress syndrome and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
    • acute ards respiratory distress syndrome and lung hemorrhage: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
    • acute ards respiratory distress syndrome cause and loading dose: 1
    • acute ards respiratory distress syndrome cause and local inflammatory response: 1
    • acute ards respiratory distress syndrome cause and low normal: 1
    • acute ards respiratory distress syndrome cause and lung function: 1
    • acute ards respiratory distress syndrome cause and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute respiratory syndrome and adenosine nucleotide: 1, 2
    • acute respiratory syndrome and adenosine nucleotide analog: 1